CanSino Biologics Inc.
About CanSino Biologics Inc.
Certifications
-
GMP
Categories
-
Country/Region:China
-
On CPHI since:2024
-
Certificates:1
-
Employees:1000 - 4999
Company types
Primary activities
Products from CanSino Biologics Inc. (3)
-
Product Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) Menhycia®
More Serogroup: Men ACWY
Long lasting: immunization memory, High affinity IgG, Mucosal immunity.
Strong Evidence: A 10-year evidence of MenACWY CRM Menhycia® evidence.
Saftey: A 10-year evidence of Men ACWY CRM Menhycia® evidence Safety of CRM 197
... -
Product 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT)
Active immunization for the prevention of invasive diseases (including bacteremic pneumonia, meningitis, sepsis, bacteremia, etc.) caused by Streptococcus pneumoniae serotypes of 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in infants and children from 2 months (minimum 6 weeks) to 5 years of age. -
Product Group A and Group C Meningococcal Conjugate Vaccine (CRM197) Menphecia®
• China's first bivalent meningococcal conjugate vaccine using CRM197 vector • Provides protection against two serotypes (group A and group C) • Safer and better